Document is current

Article History

Received: 1 December 2023

Accepted: 17 January 2024

First Online: 2 February 2024

Declarations

:

: The study was approved by the ethical committees of participating centers (Comitato Etico Regione Lombardia Sezione Fondazione IRCCS Istituto Neurologico Carlo Besta; Comitato Etico della Fondazione Policlinico Campus Bio-Medico) and was conducted in agreement with the Declaration of Helsinki and the Good Clinical Practice. Due to the retrospective nature of the study on already available anonymous data, which were previously collected for other research purposes with patient consent, another informed consent procedure was not deemed necessary and the need of a new consent procedure was waived.

: Not applicable.

: Licia Grazzi received consultancy and advisory fees from Abbvie, Eli-Lilly, Lundbeck, Novartis AG, Pfizer, and TEVA Pharm Ind. Riccardo Giossi received support for congress participation from Mylan and acted as a consultant for Daiichi-Sankyo, outside this work. Claudia Altamura is associated editor for Frontiers of Human Neuroscience and received travel grants and/or personal fees for advisory boards and speaker panels, from Novartis, Eli-Lilly, Lundbeck, Teva, Lusofarmaco, Laborest, Abbvie/Allergan, Almirall, and Pfizer. Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Abbvie/Allergan, Amgen, Angelini, Eli-Lilly, Lundbeck, Novartis, Pfizer, and Teva. Other Authors have nothing to disclose.